MetaCap

Altimmune (ALT) vs Vicore Pharma AB (VCRE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Vicore Pharma AB is the larger company by market cap ($264.9 million vs $258.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALT-56.82%VCRE-42.12%
+14%-23%-60%
Jul 6, 20261 yearNov 20, 2026
ALT-56.39%VCRE-31.75%
+16%-22%-60%
Jul 6, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALT versus VCRE key metrics
MetricALTVCRE
Share price$1.33$9.41
Market cap$258.80M$264.89M
1-day change-5.67%-5.09%
YTD return-63.16%—
1-year return-72.35%—
5-year return-87.24%—
EPS (TTM)$-0.71$-2.04
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$41.00K—
Revenue growth (YoY)+105.00%—
Net income (latest FY)$-88.09M—
Operating margin-230460.98%—
Net margin-214860.98%—
52-week high$6.44$17.80
52-week low$1.32$7.88
Distance from 52-week high-79.35%-47.16%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1127.82%+158.90%
Average volume3.91M23.31K
Shares outstanding194.59M28.16M
Employees5750
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Altimmune

ALT stock →

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees

About Vicore Pharma AB

VCRE stock →

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.

Health Care · Biotechnology: Pharmaceutical Preparations · 50 employees

ALT vs VCRE FAQ

Which is bigger, Altimmune or Vicore Pharma AB?

Vicore Pharma AB (VCRE) is larger, with a market capitalization of $264.89M compared with $258.80M for Altimmune (ALT).

Are Altimmune and Vicore Pharma AB in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons